SCHEMBL24710856

SCHEMBL24710856

COc1c(Cl)cc(C(=O)Nc2cc(-c3nc4cc(Cl)ccc4o3)ccc2C)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 5/20 0.70
▸ TP53 P04637 10/20 0.69
▸ SMN1; SMN2 Q16637 3/20 0.69
▸ NPC1 O15118 1/20 0.69
▸ USP2 O75604 1/20 0.69
▸ HTT P42858 1/20 0.69
▸ RAB9A P51151 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ LMNA P02545 2/20 0.68
▸ MAPT P10636 7/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ KMT2A Q03164 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24710832 0.90 TP53 (0.66) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL3456134 0.82 THRB (0.67) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL5390213 0.80 MAPT (0.67) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL24711515 0.79 TP53 (0.80) TP53SMN1; SMN2NPC1USP2HTT
SCHEMBL24711778 0.78 MAPT (0.68) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL24711202 0.75 MAPT (0.66) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL27188314 0.73 MAPT (0.78) THRBTP53LMNAMAPTRXFP1
SCHEMBL24711203 0.72 MAPT (0.70) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL24710963 0.72 TP53 (0.61) THRBTP53SMN1; SMN2NPC1USP2
SCHEMBL4522299 0.71 MAPT (0.64) THRBTP53SMN1; SMN2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 THRB 3139/4885TP53 673/4885SMN1; SMN2 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback